PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification

• Y Green,
• I Parodis,
• RA Levy,
• JA Gilbride,
• L Liefaard,
• C Henning,
• R Dimelow

Affiliations

Y Green

3Novartis Horsham Research Centre, Horsham, West Sussex, UK

I Parodis

1Karolinska Institutet, Stockholm, Sweden

RA Levy

4GlaxoSmithKline, Global Medical Affairs ~ Collegeville ~ USA

JA Gilbride

5GlaxoSmithKline, RandD Biostatistics ~ Stevenage ~ UK

L Liefaard

2GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation ~ Stevenage ~ UK

C Henning

5GlaxoSmithKline, Global Medical Affairs ~ Research Triangle Park, NC ~ USA

R Dimelow

2GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation ~ Stevenage ~ UK